中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 首次公开发行部分限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为益方生 物科技（上海）股份有限公司（以下简称"益方生物"或"公司"）首次公开发 行股票并上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创 板股票上市规则》等相关法律、法规和规范性文件的规定，对益方生物本次首次 公开发行部分限售股上市流通事项进行了核查，核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 4 月 1 日出具的《关于同意益方生 物科技（上海）股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕 682 号），同意益方生物科技（上海）股份有限公司（以下简称"公司"）首次公 开发行股票的注册申请。公司首次向社会公众公开发行人民币普通股（A 股）股 票 115,000,000 股，并于 2022 年 7 月 25 日在上海证券交易所科创板上市，发行 完成后总股本为 575,000,000 股，其中有限售条件流 ...

Core Viewpoint - The overdue payment of 180 million yuan by Betta Pharmaceuticals to Yifang Biotech for the innovative lung cancer drug, Beifu Tian, has highlighted the survival pressures faced by both companies and raised concerns about the credit system in the innovative drug industry [1][9]. Group 1: Payment Dispute Details - Yifang Biotech disclosed that Betta Pharmaceuticals has owed 180 million yuan for nearly two years, despite multiple communications and a formal payment reminder sent at the end of 2024 [1][2]. - The cooperation agreement between Yifang Biotech and Betta Pharmaceuticals, established in December 2018, stipulated that Betta would pay a total of 230 million yuan in initial and milestone payments for the drug's development and commercialization [1][2]. - Betta Pharmaceuticals initially paid 55.3 million yuan in 2019, but subsequent milestone payments totaling 180 million yuan were delayed due to claims of "funding arrangements" [2][4]. Group 2: Financial Implications for Yifang Biotech - Yifang Biotech's revenue for 2024 was approximately 169 million yuan, entirely derived from technology licensing and cooperation, making the overdue payment critical for its funding [4][9]. - The company has recognized a bad debt provision of 18 million yuan, reflecting its expectation of non-receipt of the overdue payment [1][4]. Group 3: Financial Condition of Betta Pharmaceuticals - Betta Pharmaceuticals reported a revenue of 2.892 billion yuan and a net profit of 403 million yuan for 2024, with a year-on-year increase of 17.74% and 15.67%, respectively [7][8]. - The company has faced significant cash flow pressures, with a 37.23% decrease in cash reserves to 472 million yuan by the end of 2024, and a current ratio below 1 for three consecutive years [7][8]. Group 4: Market Competition and Challenges - Beifu Tian, as a third-generation EGFR inhibitor, faces intense competition from established products like Osimertinib and Aumolertinib, which has impacted its market performance [5][6]. - The sales performance of Betta's other products has also been under pressure, with significant declines in sales growth and profit margins [5][6]. Group 5: Industry Credit System Concerns - The overdue payment issue has sparked discussions about the credit system in the innovative drug industry, emphasizing the need for transparency and trust in business collaborations [9][10]. - Experts have pointed out the risks associated with unclear contract terms and the importance of financial planning and trust in maintaining long-term partnerships [10].

Group 1 - The core viewpoint of the news highlights the positive market reaction to the National Healthcare Security Administration's initiation of the 11th batch of drug procurement, which protects the profit margins of innovative drug companies by excluding them from the procurement scope [1] - The Sci-Tech Innovation Biomedicine ETF (588250.SH) rose by 0.26%, while its associated index, Sci-Tech Biomedicine (000683.SH), increased by 0.28% [1] - Key constituent stocks such as Yifang Biotech-U, Borui Pharmaceutical, and Nanwei Medical saw significant gains, with increases of 4.49%, 3.08%, and 3.84% respectively, indicating a strong performance in the innovative drug sector [1] Group 2 - According to West Securities, the Sci-Tech Biomedicine index has a distinct industry distribution, with chemical pharmaceuticals accounting for 38.75% and medical devices for 39.10%, which is significantly higher than other indices [2] - The index has shown a return rate exceeding 10% since 2025, although it exhibits relatively high volatility [2] - The index's constituent stock structure has a low overlap with other mainstream pharmaceutical indices, reflecting its unique sci-tech attributes [2]

Core Viewpoint - The innovative drug market is experiencing a surge in interest and investment, with significant inflows of capital and strong performance in related stocks [1][5]. Group 1: Market Performance - On July 15, the pharmaceutical ETF (562050) experienced a sharp increase during the opening auction, indicating heightened investor enthusiasm for innovative drugs [2][3]. - The ETF closed up 0.59% at 1.017 yuan per share, with a total trading volume of approximately 26.34 million yuan and a turnover rate of 22.94% [4]. - A-shares in innovative drugs have shown notable gains, with companies like ShenZhou Cell rising nearly 50% in the past month, and others like BoRui Medicine and Jilin AoDong increasing over 10% [5]. Group 2: Fund Performance and Strategy - The latest public fund reports reveal a significant shift towards innovative drugs, with the Changcheng Pharmaceutical Industry Selected Fund achieving over 90% returns, increasing its scale nearly 30 times in the second quarter [6][9]. - The fund manager of Yongying Medical Health Fund indicated a complete portfolio overhaul towards innovative drugs, with top holdings including ShuTaiShen and Rejing Biology, the latter seeing a staggering 443.59% increase this year [6][7]. - The Changcheng fund plans to continue focusing on innovative drugs in the third quarter, emphasizing clinical data, overseas licensing, and domestic sales growth [8]. Group 3: Policy and Market Trends - The innovative drug sector is benefiting from favorable policy developments, with the National Medical Insurance Bureau initiating adjustments to the drug catalog for 2025 [10]. - Data shows that the total amount for Chinese innovative drug licenses reached nearly 66 billion USD in the first half of 2025, surpassing the total for 2024, indicating a rapid rise in global competitiveness [11]. - The current market rally is primarily driven by clinical results and expectations for overseas licensing, with a focus on companies that have the potential for international expansion and those that have successfully transformed [11].

Group 1 - The core viewpoint of the article highlights the performance of public funds in the second quarter of 2025, with a focus on the innovative drug sector and the significant increase in short-term bond fund shares [1][4] - The first report from the outstanding fund manager Liang Furui shows a cumulative net value growth rate of 75.18% for the Changcheng Pharmaceutical Industry Select Fund, making it the second-best performing equity fund in the first half of the year [2] - Liang Furui's report indicates that the innovative drug development will focus on overseas licensing and domestic sales expansion in the third quarter, with a continued emphasis on clinical data, pipeline licensing, and sales growth [3] Group 2 - Several short-term bond funds have seen a significant increase in shares during the second quarter, with the Debang Short Bond Fund's total shares rising to 5.482 billion, an increase of over 30 billion shares, representing a growth of over 125% [4] - The fund managers of Dongfanghong Yixin Pure Bond and Dongfanghong Short Bond report that the next phase will focus on benefiting from internal liquidity easing, with a core strategy of investment-grade leverage and duration trading [4][5] - The Debang Short Bond Fund managers express concerns about external demand pressures and the potential slowdown of the "old-for-new" subsidy policy, while maintaining a positive outlook for the bond market in the third quarter [5]

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]

Summary of Key Points Core Viewpoint - On July 11, 13 stocks from the Sci-Tech Innovation Board experienced block trading, with a total transaction amount of 256 million yuan, indicating active trading in this sector [1]. Group 1: Trading Activity - A total of 13 Sci-Tech Innovation Board stocks had block trades, with 26 transactions and a cumulative trading volume of 13.93 million shares [1]. - The stock with the highest transaction amount was Weiteng Electric, with a trading volume of 2.34 million shares and a transaction amount of 63.52 million yuan [1]. - Other notable stocks in terms of transaction amounts included Huicheng Co. and Yunzhu Technology, with transaction amounts of 57.27 million yuan and 23.83 million yuan, respectively [1]. Group 2: Price Performance - The average price of the stocks involved in block trading showed a discount compared to the closing price, with the highest discount rates for Weimais, Dameng Data, and Fuje Environmental Protection at 25.02%, 21.16%, and 19.12% respectively [1]. - In contrast, Huicheng Co. had a premium rate of 0.93% [1]. - The Sci-Tech 50 Index rose by 1.48%, with 402 stocks (68.25%) increasing in value, while the average increase for stocks involved in block trading was 3.58% [1]. Group 3: Institutional Participation - Among the block trades, 12 transactions involved institutional buyers or sellers, focusing on four stocks, with the highest buying amounts in Fuje Environmental Protection, Aopumai, and Yifang Bio at 14.08 million yuan, 10.49 million yuan, and 10.01 million yuan, respectively [2]. - Net inflows of funds were observed in six stocks, with Yifang Bio, Huazhu High-Tech, and Kaiweite leading in net inflow amounts of 16.69 million yuan, 5.53 million yuan, and 5.47 million yuan, respectively [2]. - Conversely, Yunzhu Technology, Haimeixing, and Fuchuang Precision experienced the highest net outflows of 8.99 million yuan, 7.35 million yuan, and 3.13 million yuan, respectively [2].

Core Viewpoint - The innovation drug sector is experiencing positive developments with the official launch of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory and the Commercial Health Insurance Innovation Drug Directory adjustment [1][4]. Group 1: Policy Changes - The National Healthcare Security Administration (NHSA) has initiated the adjustment of the drug directories, allowing eligible applicants to submit online applications from July 11 to July 20 [4]. - The newly added commercial health insurance innovation drug directory focuses on high innovation, significant clinical value, and substantial patient benefits, which cannot be included in the basic directory due to exceeding the "basic protection" scope [4][5]. - The NHSA has released a series of documents outlining the adjustment work plan, including guidelines for the new commercial health insurance innovation drug directory [2][4]. Group 2: Market Reactions - The innovation drug sector has shown strong performance in the secondary market, with the Wind Innovation Drug Index rising over 2% on July 11, and several companies like Yifang Bio and Changshan Pharmaceutical seeing significant stock price increases [3][4]. - Multiple brokerages express optimism about the innovation drug sector and its related industrial chain, indicating a positive outlook for future investments [3][6]. Group 3: Institutional Support - The NHSA and the National Health Commission have issued measures to support high-quality development of innovation drugs, encouraging the use of healthcare data for drug research and promoting investment in innovation drugs by commercial health insurance [6][7]. - The measures also propose the establishment of a commercial health insurance innovation drug directory, which will include drugs that exceed basic insurance coverage but have high innovation and clinical value [6][7]. Group 4: Industry Growth Potential - Analysts highlight that the innovation drug sector has maintained rapid growth in product revenue and external licensing over the past three years, with significant business development (BD) transactions occurring this year [7][8]. - The increasing international competitiveness of Chinese innovation drug assets is noted, with clinical data gaining prominence at academic conferences and BD transactions on the rise [8][9].

Core Viewpoint - The Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index has shown strong performance, with significant increases in constituent stocks, indicating a positive trend in the biopharmaceutical sector [1][3]. Market Performance - As of July 11, 2025, the Biopharmaceutical Index rose by 1.23%, with notable gains from stocks such as Yifang Biotech (+10.31%), Shouyao Holdings (+8.34%), and Te Bao Biotech (+7.18%) [1]. - The Jiashi Science and Technology Medicine ETF (588700) also increased by 1.14%, marking its third consecutive rise [1]. Liquidity and Trading Volume - The Jiashi Science and Technology Medicine ETF recorded a turnover rate of 9.54% and a trading volume of 21.11 million yuan [3]. - Over the past month, the ETF has maintained an average daily trading volume of 33.32 million yuan, ranking first among comparable funds [3]. Fund Growth and Performance - In the last two weeks, the Jiashi Science and Technology Medicine ETF's scale increased by 17.56 million yuan, leading among comparable funds [3]. - The ETF's net value has risen by 37.70% over the past year, with a maximum single-month return of 23.29% since its inception [3]. Top Holdings - As of June 30, 2025, the top ten weighted stocks in the Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare, BeiGene, and Huatai Medical [3][5]. Policy Support and Market Outlook - Recent policy documents have been released to support the high-quality development of innovative drugs, highlighting government backing for the sector [6]. - The number of innovative drugs in development in China has reached over 4,000, representing approximately 30% of the global total [5][6].

Core Viewpoint - The innovative drug concept continues to show strong performance, with significant stock price increases for companies such as Boteng Co. and Changshan Pharmaceutical, which rose over 15% [1] Group 1: Stock Performance - Boteng Co. and Changshan Pharmaceutical saw stock increases of over 15% [1] - WuXi AppTec experienced a nearly 9% rise [1] - Other companies like Kylin Pharmaceutical, Guangsheng Pharmaceutical, and Yifang Bio also saw stock increases of over 5% [1] Group 2: Policy Announcement - On July 10, the National Healthcare Security Administration announced the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog [1] - The plan specifies that the adjustments to the basic medical insurance drug catalog and the establishment of the commercial health insurance innovative drug catalog will occur simultaneously in 2025 [1]